GSK has agreed to pay up to $2.2 billion to settle most lawsuits in US state courts claiming that a discontinued version of ...

The British drugmaker reached a $2.2 billion settlement to resolve around 80,000 lawsuits over claims its Zantac heartburn ...

GSK shares jumped as much as 6.5% on Thursday after the British drugmaker struck a $2.2 billion settlement over U.S. lawsuits ...

The FDA has asked drugmakers to pull all prescription and over-the-counter products based on ranitidine off the market immediately, after a review failed to alleviate concerns about a cancer risk.

GSK Plc shares surged after the UK pharma company agreed to pay as much as $2.2 billion to resolve about 80,000 US court ...

GSK, which developed and sold versions of the now-discontinued blockbuster heartburn drug, agreed to pay up to $2.2 billion.

GSK has agreed to pay $2.2bn to settle about 80,000 Zantac lawsuits in the US. In a statement released after the close of ...

Zantac was pulled from shelves in 2019 amid panic that a key ingredient - ranitidine - could cause cancer, plunging GSK and ...

Pharmaceutical giant GSK will pay up to £1.7billion to settle thousands of legal cases that claimed its heartburn drug Zantac ...

GSK said late Wednesday that it agreed to settle a vast majority of lawsuits concerning its discontinued heartburn medicine Zantac. "GSK Shares Climb on $2.2 Bln Zantac Lawsuit Settlement," at 0754 ...

GSK has agreed to pay up to $2.2 billion to settle most lawsuits in U.S. state courts claiming that a discontinued version of ...